4D Molecular Therapeutics (FDMT) Stock Price, News & Analysis

Company Overview

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas. Notable programs target inherited retinal disorders—such as X-linked retinitis pigmentosa and achromatopsia—as well as investigational candidates for neuromuscular and metabolic diseases. By tailoring capsid design to specific tissues, the company seeks to optimize safety and efficacy in patient populations with high unmet medical need.

To support its research and development efforts, 4D Molecular Therapeutics engages in collaborations with academic institutions and industry partners in the United States and Europe. The company completed its initial public offering in October 2017, trading on the NASDAQ under the symbol FDMT, and has used the proceeds to advance its clinical and preclinical programs.

The company is led by President and Chief Executive Officer John J. Falcon, whose leadership team comprises experienced professionals in gene therapy development, regulatory affairs and commercial strategy. Under Falcon’s guidance, 4D Molecular Therapeutics continues to advance its innovative platform with the goal of delivering transformative treatments to patients suffering from rare genetic disorders.

Key Stats

• Today's Range: $9.66 to $10.33
• 50-Day Range: $8.60 to $13.30
• 52-Week Range: $5.11 to $14.00
• Volume: 207,552 shs
• Average Volume: 800,141 shs
• Market Capitalization: $521.71 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $30.67
• Consensus Rating: Moderate Buy

4D Molecular Therapeutics Stock Analysis - MarketRank™

4D Molecular Therapeutics scored higher than 71% of companies evaluated by MarketBeat, and ranked 211th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

4D Molecular Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 7 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

4D Molecular Therapeutics has a consensus price target of $30.67, representing about 205.9% upside from its current price of $10.03.

Amount of Analyst Coverage

4D Molecular Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for 4D Molecular Therapeutics are expected to grow in the coming year, from ($3.81) to ($3.59) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of 4D Molecular Therapeutics is -3.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of 4D Molecular Therapeutics is -3.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

4D Molecular Therapeutics has a P/B Ratio of 1.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

23.60% of the float of 4D Molecular Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

4D Molecular Therapeutics has a short interest ratio ("days to cover") of 15.51, which indicates bearish sentiment.

Change versus previous month

Short interest in 4D Molecular Therapeutics has recently decreased by 14.59%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

4D Molecular Therapeutics does not currently pay a dividend.

Dividend Growth

4D Molecular Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.90

News Sentiment

4D Molecular Therapeutics has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for 4D Molecular Therapeutics this week, compared to 4 articles on an average week.

Search Interest

8 people have searched for FDMT on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added 4D Molecular Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, 4D Molecular Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,075,906.00 in company stock.

Percentage Held by Insiders

7.90% of the stock of 4D Molecular Therapeutics is held by insiders.

Percentage Held by Institutions

99.27% of the stock of 4D Molecular Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 8/03/2026
• Next Earnings (Estimated): 8/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:FDMT
• CIK: 1650648
• Web: www.4dmoleculartherapeutics.com
• Phone: 510-505-2680
• Fax: N/A
• Employees: 120
• Year Founded: 2013

Price Target and Rating

• Average Price Target for 4D Molecular Therapeutics: $30.67
• High Price Target: $38.00
• Low Price Target: $17.00
• Potential Upside/Downside: +207.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.57)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$140.11 million
• Net Margins: -182.34%
• Pretax Margin: -182.34%
• Return on Equity: -36.83%
• Return on Assets: -32.55%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.34
• Quick Ratio: 9.34

Sales & Book Value

• Annual Sales: $88.24 million
• Price / Sales: 5.91
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.85 per share
• Price / Book: 1.13

Miscellaneous

• Outstanding Shares: 52,276,000
• Free Float: 48,146,000
• Market Cap: $521.71 million
• Optionable: Optionable
• Beta: 2.70